**Name of journal:** ***World Journal of Gastroenterology***

**ESPS Manuscript NO: 25724**

**Manuscript type: Topic Highlight**

**2016 Colorectal Cancer: Global view**

**genomic diversity of colorectal cancer: changing landscape and emerging targets**

Ahn DH *et al*. **colorectal cancer, genomics, targeted therapy**

**Daniel H Ahn,Kristen K Ciombor,Sameh Mikhail, Tanios Bekaii-Saab**

**Daniel H Ahn, Tanios Bekaii-Saab**, Division of Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, United States

**Kristen K Ciombor, Sameh Mikhail**, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, United States

**Author contributions:** All authors contributed to this paper with conception, drafting, revision and approval of the final version of the paper.

**Conflict-of-interest statement:** None of the authors have any potential conflicts of interest, and no financial support was used for the work of this paper.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Tanios Bekaii-Saab, MD,** Division of Medical Oncology, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85054, United States. [tanios.saab@gmail.com](mailto:tanios.saab@gmail.com)

**Telephone:** +1-614-2939863

**Fax:** +1-614-2937529

**Received:** March 20, 2016

**Peer-review started:** March 22, 2016

**First decision:** May 12, 2016

**Revised:** May 20, 2016

**Accepted:** June 13, 2016

**Article in press:**

**Published online:**

**Abstract**

Improvements in screening and preventive measures have led to an increased detection of early stage colorectal cancers (CRC) where patients undergo treatment with a curative intent. Despite these efforts, a high proportion of patients are diagnosed with advanced stage disease that is associated with poor outcomes, as CRC remains one of the leading causes of cancer-related deaths in the world. The development of next generation sequencing and collaborative multi-institutional efforts to characterize the cancer genome has afforded us with a comprehensive assessment of the genomic makeup present in CRC. This knowledge has translated into understanding the prognostic role of various tumor somatic variants in this disease. Additionally, the awareness of the genomic alterations present in CRC has resulted in an improvement in patient outcomes, largely due to better selection of personalized therapies based on an individual’s tumor genomic makeup. The benefit of various treatments is often limited, where recent studies assessing the genomic diversity in CRC have identified the development of secondary tumor somatic variants that likely contribute to acquired treatment resistance. These studies have begun to alter the landscape of treatment for CRC that include investigating novel targeted therapies, assessing the role of immunotherapy and prospective, dynamic assessment of changes in tumor genomic alterations that occur during the treatment of CRC.

**Key words:** colorectal cancer; *KRAS* mutation; *BRAF* mutation; genomic diversity; tumor DNA

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tips:** Tumor somatic variants have a prognostic role, in addition to treatment selection in patients with solid tumor malignancies, including colorectal cancer (CRC).The application of this knowledge in the development of novel, targeted therapies has resulted in improved patient outcomes in this disease. Our objective is to provide an overview of the genomic alterations present in CRC and its role in treatment implications, in addition to providing an overview of ongoing and future clinical trials.

Ahn DH,Ciombor KK,Mikhail S, Bekaii-Saab T. genomic diversity of colorectal cancer: changing landscape and emerging targets. *World J Gastroenterol* 2016; In press

**Introduction**

Colorectal cancer (CRC) is the fourth most common cancer in the world, leading to more than 500,000 deaths annually[[1](#_ENREF_1),[2](#_ENREF_2)]. An increased awareness of the genomic makeup of CRC has allowed us to understand the prognostic role of certain tumor genomic alterations. This knowledge and its incorporation into the treatment of metastatic CRC has translated to significant improvements in patient outcomes, where patients’ median overall survival has approached 3 years[[3-5](#_ENREF_3)]. The incorporation of our knowledge about the genomic landscape of CRC into treatment decisions with selected targeted agents has led to an improvement in patient outcomes. With this increased understanding, clinical trials are now being designed to assign treatment selection with novel therapies based upon identified specific tumor somatic variants in each individual. Herein we review the genomic landscape of CRC, its current role in treatment selection, and its integration in ongoing and future studies.

**Genomic alterations in downstream signaling pathways in CRC**

***RAS Mutations in CRC***

The Kirsten Ras (*KRAS*) oncogene encodes for a guanosine triphosphate (GTP)/guanosine diphosphate binding protein downstream of the extracellular epidermal growth factor receptor in the RAS/RAF/MAPK signaling pathway. Activating *KRAS* exon 2 mutations occur in up to 45% of all CRC, and are involved in initiation, proliferation and progression of CRC[[6-10](#_ENREF_6)]. While initial studies suggested a possible clinical benefit from anti-epidermal growth factor receptor (EGFR) therapy for patients whose tumors express *KRAS* codon 13 (G13D) mutations, a meta-analysis comprised of several large phase III trials failed to demonstrate benefit from panitumumab, an anti-EGFR monoclonal antibody, in CRC patients whose tumor harbored a *KRAS* codon 13 mutation[[11](#_ENREF_11)]. In addition to *KRAS* exon 2, an approximate additional 10% of patients with other *RAS* mutations have been identified in CRC, including *NRAS* or non-exon 2 *KRAS* mutations[[6](#_ENREF_6)]. In patients who exhibited activating non-exon 2 *KRAS* and *NRAS* mutations, an absence of clinical benefit, and perhaps a negative effect, was seen from the addition of anti-EGFR therapy in combination with several chemotherapy regimens in various treatment settings[[6](#_ENREF_6),[12](#_ENREF_12),[13](#_ENREF_13)]. On this basis, anti-EGFR therapy should not be given to any patient with CRC exhibiting a *RAS* mutation.

While mutations in *RAS* as a predictive biomarker to anti-EGFR therapy has been recognized, its relevance as a therapeutic target is unknown. Given the high incidence of *RAS* in CRC and its importance as an oncogene, targeting *RAS* represents an ideal and promising strategy. Developing strategies to directly block oncogenic *RAS* activity has remained a challenge due to several factors, including the high binding affinity of the oncoprotein to the GTP-bound “on” state, as well as the lack of accessibility to active sites within *KRAS* to bind[[14](#_ENREF_14)]. One alternative approach includes targeting pathways and its effectors downstream of *RAS*. The clinical benefit from targeting single pathways is often limited due to mechanisms of resistance including communication between signaling pathways and its resulting downstream effector activation and inhibition through a feedback loop mechanism[[15](#_ENREF_15),[16](#_ENREF_16)]. Alternatively, secondary treatment resistance to anti-EGFR treatment may result from the development of *RAS* mutations during a course of anti-EGFR therapy. Several studies have demonstrated up to 96% of patients who initially had *RAS* and *BRAF* wild-type CRC were later identified to have acquired activating RAS (*KRAS* or *NRAS*) or *BRAF* mutations on repeat tumor genomic assessment at the time of disease progression on anti-EGFR therapy[[17-19](#_ENREF_17)].

Alternative treatment strategies in *RAS* mutant CRC include the combination of various therapeutic agents targeting several genes involved in the *MAPK* pathway that would cause sufficient suppression of activated *RAS* activity. Combining small molecule inhibitors of *MEK* to anti-EGFR therapies have demonstrated the reversal of acquired anti-EGFR therapy resistance, prompting ongoing clinical trials investigating the clinical utility of the combination of multiple signaling pathway inhibitors in the first-line setting, as well as in salvage therapy for refractory disease (Table 1). Targeting multiple signaling pathways may also be effective in overcoming resistance from secondary activation of parallel signaling pathways[[20](#_ENREF_20)]. Alternatively, administering anti-EGFR therapies in a pulsatile manner instead of to the point of clinical progression may prolong anti-EGFR therapy efficacy. A recent study that performed dynamic monitoring of tumor somatic variants through circulating tumor DNA demonstrated a decrease in drug resistant KRAS clones upon withdraw of cetuximab, allowing for the reemergence of drug sensitivity to anti-EGFR therapy[[21](#_ENREF_21)]. This suggests a rationale for intermittent EGFR blockade, and explains for the seldom efficacy seen with re-challenging anti-EGFR therapies. Lastly, inhibitors of the MAPK and PI3K/Akt/mTOR pathway are considered to cause G1 cell cycle arrest through the suppression of D-type cyclins and the upregulation of cell cycle inhibitors[[22](#_ENREF_22),[23](#_ENREF_23)]. Pre-clinical studies have demonstrated potent inhibition of G1/S transition and phosphorylation of retinoblastoma (Rb) protein with the inhibition of the MAPK and PI3K/Akt pathway[[24](#_ENREF_24)]. The combination of MEK and CDK inhibitors may be considered a potential strategy in treating RAS activated CRC or in tumors harboring mutations in CDK.

***BRAF mutations in CRC***

*BRAF* *V600E* mutations occur in up to 5% of metastatic CRC[[25](#_ENREF_25),[26](#_ENREF_26)] and are often associated with a more aggressive phenotype (with the exception in microsatellite instability high CRC, where the effect is attenuated). Patients with *BRAF* *V600E* mutations tend to respond poorly to conventional chemotherapy and have worse outcomes[[6](#_ENREF_6),[27-31](#_ENREF_27)]. The constitutive activation of *BRAF* evading any upstream inhibition of EGFR may explain the limited clinical benefit seen with anti-EGFRtherapies in *BRAF* mutant metastatic CRC[[6](#_ENREF_6),[32](#_ENREF_32),[33](#_ENREF_33)].

In metastatic melanoma, inhibition of *BRAF* with small molecule inhibitors has led to improvement in clinical outcomes in patients whose tumors exhibit mutations in *BRAF*[[34-37](#_ENREF_34)]. However, the clinical efficacy from single agent *BRAF* inhibition has not translated to patients with *BRAF* mutant metastatic CRC[[36](#_ENREF_36),[38](#_ENREF_38)]. The lack of anti-tumor activity may be a result of insufficient inhibition of the *MAPK* pathway as a result of a feedback loop mechanism, resulting in the persistent activation of the *MAPK* signaling pathway[[16](#_ENREF_16),[39](#_ENREF_39)] (Figure 1). To overcome this compensatory mechanism, the combination of tyrosine kinase inhibitors aimed at inhibiting the *MAPK* pathway has resulted in an improvement in treatment efficacy in comparison to single-agent *BRAF* small molecule inhibitor in metastatic melanoma[[40](#_ENREF_40)]. Based on these results, a phase II study investigating the clinical activity from the combination of *BRAF* and *MEK* inhibition with dabrafenib and trametinib was conducted in patients with *BRAF* mutant metastatic CRC[[41](#_ENREF_41)]. While modest clinical activity was observed with the combination, with 12% of patients experiencing either a partial or complete response, correlative laboratory studies suggest an inhibition in *MAPK* signaling in patients receiving the combination[[37](#_ENREF_37)]. The absence of significant anti-tumor activity may be attributed to insufficient suppression of *MAPK* signaling, which may be due to upstream activation of EGFR*,* leading to reactivation of *MAPK* and other integral signaling pathways[[15](#_ENREF_15)]. Based on this rationale, ongoing studies are investigating the combination of anti-EGFR therapies with *BRAF* tyrosine kinase inhibitors in patients with *BRAF* mutant mCRC (Table 1)[[42-45](#_ENREF_42)].

**Genomic diversity and its role in developing personalized therapies with targeted agents in CRC**

While *RAS* mutations are the most common genomic alteration in CRC, recent efforts have allowed us to understand the genomic diversity and identify potential therapeutic targets of interest in this disease[[46](#_ENREF_46),[47](#_ENREF_47)]. Through the efforts of The Cancer Genome Atlas (TCGA), 224 CRC cases underwent extensive molecular characterization to describe the genomic landscape present in CRC[[46](#_ENREF_46)]. 24 genes were significantly mutated, where most were an actionable mutation, including ERBB2 (HER-2/neu) mutations, a therapeutic target in *HER-2* positive gastric and breast cancer, were identified in 19% of tumors[[46](#_ENREF_46)]. This comprehensive assessment allowed us to have a better understanding of the genomic landscape, in addition to identifying several potential targetable genes of interest that are essential for tumor growth and carcinogenesis that we will discuss in further detail below (Table 2).

***Fibroblast growth factor receptor in CRC***

The fibroblast growth factor receptors (FGFR)comprise a group of highly conserved tyrosine kinase receptors consisting of four members (FGFR1, 2, 3 and 4). These receptors bind to one of 18 secreted glycoprotein ligands, or fibroblast growth factors (FGFs), to their extracellular domain[[48](#_ENREF_48)]. Binding of the appropriate ligand results in FGFR dimerization, autophosphorylation and activation of downstream signaling pathways that include the *MAPK*, *PI3K/Akt* and signaling transducer and activator of transcription or STAT pathway, inducing cell differentiation, growth and survival[[49](#_ENREF_49)]. FGFR overexpression has been identified in CRC samples, where the presence of FGFR signaling has been identified as playing an important role in the tumor microenvironment, with a correlation in FGFRoverexpression with tumor invasion, advanced stage disease and chemotherapy resistance[[50-53](#_ENREF_50)]. Pre-clinical studies have demonstrated the reversal of chemotherapy resistance by combining small molecule FGFR inhibitors with chemotherapy in CRC cell lines, confirming the importance of targeting this receptor and representing a potential strategy in overcoming treatment resistance in CRC[[54](#_ENREF_54)].

***C-MET (MET)***

Hepatocyte growth factor receptor, also known as c-MET, is a proto-oncogene that encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF). Abnormal expression of c-MET through somatic mutations or overexpression has been identified in up to 66.7% of CRC samples and its microenvironment and is a negative prognostic marker related to tumor oncogenesis, invasiveness, local recurrence, and chemotherapy resistance[[55-58](#_ENREF_55)]. *MET* activation confers acquired anti-EGFR therapy resistance, through re-activation of anti-apoptotic signaling pathways, including the PI3K and MAPK pathways[[59-62](#_ENREF_59)]. Thus, inhibiting c-MET represents an emerging target of interest in the development of novel agents in CRC. Pre-clinical studies have demonstrated that the blockade of c-MET inhibits tumor growth in CRC cell lines[[63](#_ENREF_63),[64](#_ENREF_64)], thus agents targeting MET, including small molecule multi-kinase inhibitors (*e.g.,* crizotinib, tivantinib), HGF inhibitors (*e.g.,* AMG102, AV299) and immunotherapeutic agents are of interest and under investigation in the treatment of CRC.

***RET***

*RET* is located on chromosome 10q11.2 and encodes a transmembrane receptor tyrosine kinase that has three unique isoforms[[65](#_ENREF_65)]. Four ligands can bind and activate *RET*, leading to the aberrant activity of several signaling pathways including *PI3K/Akt* and *MAPK* pathway[[66](#_ENREF_66)]. While the aberrant expression of *RET* may function as an oncogene in certain solid tumor malignancies including papillary and medullary thyroid cancers[[67](#_ENREF_67)], in colorectal cancer *RET* has been identified as a tumor suppressor and as an oncogene. Studies have shown that the hypermethylation and mutational inactivation of *RET*, as well as RET fusions, promote colorectal cancer formation[[68-70](#_ENREF_68)]. In several studies, RET mutations were identified in up to 7% of mCRC samples[[46](#_ENREF_46),[71](#_ENREF_71),[72](#_ENREF_72)]. Regorafenib, an approved multi-target small molecule inhibitor in metastatic CRC[[73](#_ENREF_73)], has demonstrated tumor growth inhibition in *RET* mutant cancer cells lines[[70](#_ENREF_70),[74](#_ENREF_74)], and may explain part of its efficacy in this disease. Further studies investigating its activity in *RET* mutant CRC is warranted as it may provide further benefit in this specific cohort of CRC patients.

***HER-2/Neu***

Human growth factor receptor 2, also known as *HER-2* or *HER-2*/neu, is part of the human epidermal growth factor receptor family and has been identified as an oncogene in several solid tumor malignancies, including CRC. Its overexpression has been a poor prognostic biomarker in breast cancer and is an effective therapeutic target in breast and gastric cancer[[75-77](#_ENREF_75)]. Studies evaluating *HER-2* overexpression in CRC have identified *HER-2* somatic mutations and amplification in 7% of patients with CRC[[46](#_ENREF_46)], where pre-clinical studies have demonstrated its role in inducing resistance to anti-EGFR therapy, and its inhibition showing durable tumor regression with anti-*HER-2* therapy[[78](#_ENREF_78)]. Based on these findings, the HERACLES trial, a phase II study investigated dual anti-*HER-2* therapy blockade in patients with *HER-2* amplified (immunohistochemistry staining 3+ or 2+ with FISH positive (HER2:CEP17 ratio > 2) in > 50% of tumor cells) mCRC with previous anti-EGFR therapy. Patients received the combination of trastuzumab, an anti *HER-2* monoclonal antibody with either lapatinib, a small molecule inhibitor of *HER-2* or pertuzumab, an anti *HER-2* monoclonal antibody. Early results from the lapatinib and trastuzumab arm demonstrated a 35% response rate and median progression free survival of 5.5 mo, despite being heavily pre-treated after failing multiple lines of therapy[[79](#_ENREF_79)]. Based on these findings, anti *HER-2* therapy may be an effective treatment option in a pre-selected patient population with mCRC.

***DNA mismatch repair genes and their therapeutic relevance in advanced CRC***

Mismatch repair (*MMR*) genes function to remove erroneous DNA nucleotides during mitosis. With deficient MMR activity, altered DNA nucleotides are incorporated into cells that increase their risk in forming into a neoplastic, hypermutated makeup[[80](#_ENREF_80)], resulting in microsatellite instability. Deficient MMR activity is found in approximately 15% of CRC, in which 3% is attributed to Lynch Syndrome through germline mutations in MLH1, MSH2, MSH6, PMS2 or EPCAM3 genes[[81](#_ENREF_81),[82](#_ENREF_82)]. The remaining 12% is due to sporadic inactivation of MLH1. While microsatellite instability (MSI) is a driver for tumor formation and proliferation in CRC, recent studies have demonstrated its relevance for potential novel therapeutic agents in this cohort of CRC. Tumors expressing MSI have been characterized by an intense immune infiltration, likely related to a high density of mutations, creating numerous neo-antigens and targets for immune therapies. Based on this rationale, a single-arm phase II study was conducted to assess the clinical efficacy of pembrolizumab, a programmed cell death protein (PD)-1 inhibitor, in patients with treatment resistant, metastatic cancer that did or did not express mismatch-repair deficiency[[83](#_ENREF_83)]. Individuals with deficient MMR colorectal cancer experienced a response rate of 40% and immune-related PFS of 78% at 20 weeks. Interestingly, a lack of activity was associated with mismatch repair-proficient CRC patients, confirming that immunotherapeutic agents may be beneficial in only certain cohorts of CRC, unless alternative approaches can be developed to transform tumors into an immune-responsive phenotype[[83](#_ENREF_83)]. Based on these findings, several ongoing clinical trials are investigating various novel, immunotherapeutic agents in the treatment of CRC that include studies in patients with MSI high tumors and those with positive PDL-1 expression (Table 3). While current trials will substantiate the role of immune therapy in CRC, a better understanding of mechanisms of acquired resistance, optimal duration of necessary treatment and predictive biomarkers associated with treatment efficacy are paramount.

***Tumor genomic assessment at the time of acquired therapy resistance in mCRC***

While anti-tumor activity from targeted therapies can lead to dramatic responses, the clinical benefit is often limited due to inherent and acquired resistance through the acquisition of new tumor genomic alternations, including the oncogenic activation of *MET* or acquiring *RAS* mutations, as described above. While tumor genomic alterations are usually assessed through tumor samples, obtaining tissue can be challenging due to insufficient material from tumors only accessible through fine-needle aspirates, as well as the invasive nature of such procedures.

Tumor circulating free DNA can be non-invasively assessed in peripheral blood, a “liquid biopsy,” through the assessment of circulating tumor DNA (ctDNA) and tumor cells (CTCs) and are present in advanced malignancies[[84](#_ENREF_84),[85](#_ENREF_85)]. CtDNA and CTCs can provide dynamic assessments of tumor specific mutations that may arise during the course of therapy. Although previous methodologies demonstrate low rates of sensitivity and concordance, the incorporation of new technology, including real time digital PCR has increased sensitivity (87.2%) and specificity (99.2%) in identifying tumor specific mutations responsible for treatment resistance in patients who initially responded to targeted therapies[[18](#_ENREF_18)]. While there are limitations, including false negative results as well as the inability to identify genomic alterations from central nervous system (CNS) lesions, this non-invasive tool can monitor patients for resistance-conferring mutations as well as assessing all tumors concurrently, as heterogeneity can exist between different foci of disease.

**Conclusion**

Advancements in genomic sequencing have resulted in our increased understanding of the genomic landscape of CRC, allowing us to develop and tailor personalized therapies for patients. Despite these improvements, future studies are needed to characterize and understand the functionality of the various different mutations of each gene, including mutational assessment at the time of treatment failure. This will allow us to improve therapies for patients with CRC by assessing the prognostic and potential therapeutic implication of genes of interest, and to identify predictive biomarkers of response and resistance.

**References**

1 **Siegel R**, Desantis C, Jemal A. Colorectal cancer statistics, 2014. *CA Cancer J Clin* 2014; **64**: 104-117 [PMID: 24639052 DOI: 10.3322/caac.21220]

2 **Siegel R**, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014; **64**: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]

3 **Tol J**, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. *N Engl J Med* 2009; **361**: 98-99 [PMID: 19571295 DOI: 10.1056/NEJMc0904160]

4 **Loupakis F**, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 2014; **371**: 1609-1618 [PMID: 25337750 DOI: 10.1056/NEJMoa1403108]

5 **Loupakis F,** Cremolini C, Lonardi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Valsuani C, Chiara S, Boni C, Marcucci L, Negri F, Barone C, Vitello S, D'Amico M, Granetto C, Fontanini G, Tomcikova D, Boni L, Falcone A. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. *J Clin Oncol* 2014; **32**: 3519

6 **Douillard JY**, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013; **369**: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoa1305275]

7 **Van Cutsem E**, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011; **29**: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]

8 **Peeters M**, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol* 2010; **28**: 4706-4713 [PMID: 20921462 DOI: 10.1200/JCO.2009.27.6055]

9 **Maughan TS**, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011; **377**: 2103-2114 [PMID: 21641636 DOI: 10.1016/S0140-6736(11)60613-2]

10 **Tveit KM**, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol* 2012; **30**: 1755-1762 [PMID: 22473155 DOI: 10.1200/JCO.2011.38.0915]

11 **Peeters M**, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. *J Clin Oncol* 2013; **31**: 759-765 [PMID: 23182985 DOI: 10.1200/JCO.2012.45.1492]

12 **Heinemann V**, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014; **15**: 1065-1075 [PMID: 25088940 DOI: 10.1016/S1470-2045(14)70330-4]

13 **Schwartzberg LS**, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. *J Clin Oncol* 2014; **32**: 2240-2247 [PMID: 24687833 DOI: 10.1200/JCO.2013.53.2473]

14 **Gysin S**, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. *Genes Cancer* 2011; **2**: 359-372 [PMID: 21779505 DOI: 10.1177/1947601911412376]

15 **Prahallad A**, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. *Nature* 2012; **483**: 100-103 [PMID: 22281684 DOI: 10.1038/nature10868]

16 **Corcoran RB**, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov* 2012; **2**: 227-235 [PMID: 22448344 DOI: 10.1158/2159-8290.CD-11-0341]

17 **Misale S**, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* 2012; **486**: 532-536 [PMID: 22722830 DOI: 10.1038/nature11156]

18 **Diaz LA**, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 2012; **486**: 537-540 [PMID: 22722843 DOI: 10.1038/nature11219]

19 **Bettegowda C**, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014; **6**: 224ra24 [PMID: 24553385 DOI: 10.1126/scitranslmed.3007094]

20 **Schellens J**, Van Geel R, Bendell J, Spreafico A, Schuler M, Yoshino T, Delord J, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz H, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Demuth T, Tabernero J. Final biomarker analysis of the pahse I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. Presented at the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 18-22, 2015

21 **Siravegna G**, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nat Med* 2015; **21**: 827 [PMID: 26151329 DOI: 10.1038/nm0715-827b]

22 **Leontieva OV**, Demidenko ZN, Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. *Cell Death Differ* 2013; **20**: 1241-1249 [PMID: 23852369 DOI: 10.1038/cdd.2013.86]

23 **Liu B**, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. *Oncogene* 2001; **20**: 1913-1922 [PMID: 11313939 DOI: 10.1038/sj.onc.1204277]

24 **Paternot S**, Roger PP. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. *Cancer Res* 2009; **69**: 4577-4581 [PMID: 19458076 DOI: 10.1158/0008-5472.CAN-08-3260]

25 **Davies H**, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. *Nature* 2002; **417**: 949-954 [PMID: 12068308 DOI: 10.1038/nature00766]

26 **Tie J**, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. *Int J Cancer* 2011; **128**: 2075-2084 [PMID: 20635392 DOI: 10.1002/ijc.25555]

27 **Samowitz WS**, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. *Cancer Res* 2005; **65**: 6063-6069 [PMID: 16024606 DOI: 10.1158/0008-5472.CAN-05-0404]

28 **Yokota T**, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. *Br J Cancer* 2011; **104**: 856-862 [PMID: 21285991 DOI: 10.1038/bjc.2011.19]

29 **Price TJ**, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. *J Clin Oncol* 2011; **29**: 2675-2682 [PMID: 21646616 DOI: 10.1200/JCO.2010.34.5520]

30 **Morris V**, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. *Clin Colorectal Cancer* 2014; **13**: 164-171 [PMID: 25069797 DOI: 10.1016/j.clcc.2014.06.001]

31 **Tran B**, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. *Cancer* 2011; **117**: 4623-4632 [PMID: 21456008 DOI: 10.1002/cncr.26086]

32 **Douillard JY**, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010; **28**: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]

33 **Seymour MT**, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. *Lancet Oncol* 2013; **14**: 749-759 [PMID: 23725851 DOI: 10.1016/S1470-2045(13)70163-3]

34 **Sosman JA**, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N Engl J Med* 2012; **366**: 707-714 [PMID: 22356324 DOI: 10.1056/NEJMoa1112302]

35 **Flaherty KT**, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010; **363**: 809-819 [PMID: 20818844 DOI: 10.1056/NEJMoa1002011]

36 **Falchook GS**, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. *Lancet* 2012; **379**: 1893-1901 [PMID: 22608338 DOI: 10.1016/S0140-6736(12)60398-5]

37 **Hauschild A**, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012; **380**: 358-365 [PMID: 22735384 DOI: 10.1016/S0140-6736(12)60868-X]

38 **Kopetz S**, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. *J Clin Oncol* 2015; **33**: 4032-4038 [PMID: 26460303 DOI: 10.1200/JCO.2015.63.2497]

39 **Corcoran RB**, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. *Sci Signal* 2010; **3**: ra84 [PMID: 21098728 DOI: 10.1126/scisignal.2001148]

40 **Flaherty KT**, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012; **367**: 1694-1703 [PMID: 23020132 DOI: 10.1056/NEJMoa1210093]

41 **Corcoran RB**, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. *J Clin Oncol* 2015; **33**: 4023-4031 [PMID: 26392102 DOI: 10.1200/JCO.2015.63.2471]

42 **Yaeger R**, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. *Clin Cancer Res* 2015; **21**: 1313-1320 [PMID: 25589621 DOI: 10.1158/1078-0432.CCR-14-2779]

43 **Hong DS**, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. *J Clin Oncol* 2014; **32**: 3516

44 **Tabernero J**, Chan E, Baselga J, Blay J-Y, Chau I, Hyman D, Raje N, Wolf J, Sirzen F, Veronese L, Mitchell L, Hidalgo M. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). *J Clin Oncol* 2014; **32**: 3518

45 **Atreya CE**, Van Cutsem E, Bendell JC, Schellens JHM, Gordon MS, McRee A, O'Dwyer PJ, Muro K, Tabernero J, Van Geel R, Sidhu R, Greger JG, Rangwala FA, Motwani M, Wu Y, Orford K, Corcoran RB. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). *J Clin Oncol* 2015; **33**: 103

46 [**Cancer Genome Atlas Network**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer%20Genome%20Atlas%20Network%5BCorporate%20Author%5D). Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012; **487**: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]

47 **El-Deiry WS**, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. *Cancer Biol Ther* 2015; **16**: 1726-1737 [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356]

48 **Belov AA**, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. *Cold Spring Harb Perspect Biol* 2013; **5**: [PMID: 23732477 DOI: 10.1101/cshperspect.a015958]

49 **Kouhara H**, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. *Cell* 1997; **89**: 693-702 [PMID: 9182757]

50 **Stevenson L**, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. *Clin Cancer Res* 2012; **18**: 5412-5426 [PMID: 22859720 DOI: 10.1158/1078-0432.CCR-12-1780]

51 **Bange J**, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. *Cancer Res* 2002; **62**: 840-847 [PMID: 11830541]

52 **Liu R**, Li J, Xie K, Zhang T, Lei Y, Chen Y, Zhang L, Huang K, Wang K, Wu H, Wu M, Nice EC, Huang C, Wei Y. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. *Cancer Res* 2013; **73**: 5926-5935 [PMID: 23943801 DOI: 10.1158/0008-5472.CAN-12-4718]

53 **Henriksson ML**, Edin S, Dahlin AM, Oldenborg PA, Öberg Å, Van Guelpen B, Rutegård J, Stenling R, Palmqvist R. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. *Am J Pathol* 2011; **178**: 1387-1394 [PMID: 21356388 DOI: 10.1016/j.ajpath.2010.12.008]

54 **Turkington RC**, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S, Johnston PG. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. *Cell Death Dis* 2014; **5**: e1046 [PMID: 24503538 DOI: 10.1038/cddis.2014.10]

55 **Al-Maghrabi J**, Emam E, Gomaa W, Saggaf M, Buhmeida A, Al-Qahtani M, Al-Ahwal M. c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence. *BMC Cancer* 2015; **15**: 676 [PMID: 26459369 DOI: 10.1186/s12885-015-1662-6]

56 **Di Renzo MF**, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. *Clin Cancer Res* 1995; **1**: 147-154 [PMID: 9815967]

57 **Osada S**, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. *Hepatogastroenterology* 2010; **57**: 76-80 [PMID: 20422876]

58 **Gayyed MF**, Abd El-Maqsoud NM, El-Hameed El-Heeny AA, Mohammed MF. c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. *J Gastrointest Oncol* 2015; **6**: 618-627 [PMID: 26697193 DOI: 10.3978/j.issn.2078-6891.2015.072]

59 **Bardelli A**, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov* 2013; **3**: 658-673 [PMID: 23729478 DOI: 10.1158/2159-8290.CD-12-0558]

60 **Liska D**, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. *Clin Cancer Res* 2011; **17**: 472-482 [PMID: 21098338 DOI: 10.1158/1078-0432.CCR-10-0568]

61 **Troiani T**, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. *Clin Cancer Res* 2013; **19**: 6751-6765 [PMID: 24122793 DOI: 10.1158/1078-0432.CCR-13-0423]

62 **Yonesaka K**, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K. Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. *Anticancer Res* 2015; **35**: 1683-1689 [PMID: 25750328]

63 **Sun Y**, Sun L, An Y, Shen X. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model. *Med Sci Monit* 2015; **21**: 2316-2321 [PMID: 26255947 DOI: 10.12659/MSM.893590]

64 **Song EK**, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. *Int J Cancer* 2015; **136**: 1967-1975 [PMID: 25242168 DOI: 10.1002/ijc.29225]

65 **Runeberg-Roos P**, Saarma M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. *Ann Med* 2007; **39**: 572-580 [PMID: 17934909 DOI: 10.1080/07853890701646256]

66 **Arighi E**, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. *Cytokine Growth Factor Rev* 2005; **16**: 441-467 [PMID: 15982921 DOI: 10.1016/j.cytogfr.2005.05.010]

67 **Phay JE**, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. *Clin Cancer Res* 2010; **16**: 5936-5941 [PMID: 20930041 DOI: 10.1158/1078-0432.CCR-09-0786]

68 **Luo Y**, Tsuchiya KD, Il Park D, Fausel R, Kanngurn S, Welcsh P, Dzieciatkowski S, Wang J, Grady WM. RET is a potential tumor suppressor gene in colorectal cancer. *Oncogene* 2013; **32**: 2037-2047 [PMID: 22751117 DOI: 10.1038/onc.2012.225]

69 **Mokarram P**, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H. Distinct high-profile methylated genes in colorectal cancer. *PLoS One* 2009; **4**: e7012 [PMID: 19750230 DOI: 10.1371/journal.pone.0007012]

70 **Le Rolle AF**, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK. Identification and characterization of RET fusions in advanced colorectal cancer. *Oncotarget* 2015; **6**: 28929-28937 [PMID: 26078337 DOI: 10.18632/oncotarget.4325]

71 **Seshagiri S**, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de Sauvage FJ. Recurrent R-spondin fusions in colon cancer. *Nature* 2012; **488**: 660-664 [PMID: 22895193 DOI: 10.1038/nature11282]

72 **Brannon AR**, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. *Genome Biol* 2014; **15**: 454 [PMID: 25164765 DOI: 10.1186/s13059-014-0454-7]

73 **Grothey A**, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; **381**: 303-312 [PMID: 23177514 DOI: 10.1016/S0140-6736(12)61900-X]

74 **Wilhelm SM**, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. *Int J Cancer* 2011; **129**: 245-255 [PMID: 21170960 DOI: 10.1002/ijc.25864]

75 **Verma S**, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012; **367**: 1783-1791 [PMID: 23020162 DOI: 10.1056/NEJMoa1209124]

76 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]

77 **Janjigian YY**, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. *Ann Oncol* 2012; **23**: 2656-2662 [PMID: 22689179 DOI: 10.1093/annonc/mds104]

78 **Kavuri SM**, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R. HER2 activating mutations are targets for colorectal cancer treatment. *Cancer Discov* 2015; **5**: 832-841 [PMID: 26243863 DOI: 10.1158/2159-8290.CD-14-1211]

79 **Siena S**, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Valtorta V, Torri V, Siravegna G, Amatu A, Bonazzina E, Rusconi F, Ghezzi S, Ciardiello D, Veronese S, Comoglio P, Bardelli A, Marsoni S. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. *J Clin Oncol* 2015; **33**: 3508

80 **Parsons R**, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, de la Chapelle A, Kinzler KW, Vogelstein B, Modrich P. Hypermutability and mismatch repair deficiency in RER+ tumor cells. *Cell* 1993; **75**: 1227-1236 [PMID: 8261516]

81 **Hampel H**, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med* 2005; **352**: 1851-1860 [PMID: 15872200 DOI: 10.1056/NEJMoa043146]

82 **Ligtenberg MJ**, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. *Nat Genet* 2009; **41**: 112-117 [PMID: 19098912 DOI: 10.1038/ng.283]


83 **Le DT**, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med* 2015; **372**: 2509-2520 [PMID: 26028255 DOI: 10.1056/NEJMoa1500596]

84 **Fleischhacker M**, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. *Biochim Biophys Acta* 2007; **1775**: 181-232 [PMID: 17137717 DOI: 10.1016/j.bbcan.2006.10.001]

85 **Alix-Panabières C**, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. *Annu Rev Med* 2012; **63**: 199-215 [PMID: 22053740 DOI: 10.1146/annurev-med-062310-094219]

**P-Reviewer:** Cecchin E, Li YY, Meshikhes AW **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**



**Figure 1 RAS/RAF/MEK/ERK pathway and mechanisms of resistance to *BRAF* inhibition.** The figure above shows the MAPK pathway and the compensatory feedback loop activation (arrow) despite BRAF inhibition, resulting in the upstream reactivation of the MAPK pathway.

**Table 1 Ongoing combination targeted therapy trials for colorectal cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Agent(s)** | **Class of agent** | **Phase** | **Trial number1** | **Misc** |
| MEK162 + Panitumumab | MEK tyrosine kinase inhibitor, anti-EGFR mAb | Ib/II | NCT01927341 | mCRC with mutant or wild-type RAS tumors |
| Dabrafenib + Trametinib + Panitumumab + 5-Fluorouracil | BRAF tyrosine kinase inhibitor, MEK tyrosine kinase inhibitor, anti-EGFR mAb | I/II | NCT01750918 | BRAF-V600E mutant + and in pts with secondary resistance to anti-EGFR mAb |
| LGX818 + Cetuximab +/- BYL719 | BRAF tyrosine kinase inhibitor, anti-EGFR mAb, PI3K tyrosine kinase inhibitor | I/II | NCT01719380 | BRAF mutant mCRC |
| Irinotecan + Cetuximab +/- Vemurafenib | anti-EGFR mAb, BRAF tyrosine kinase inhibitor | II | NCT02164916 | BRAF mutant mCRC |
| Neratinib + Cetuximab | HER-2 tyrosine kinase inhibitor, anti-EGFR mAb | I/II | NCT01960023 | KRAS, NRAS, BRAF, PIK3CA wild type |

1Utilizing the NCT number, clinical trial information can be obtained at <https://clinicaltrials.gov>. mAb: monoclonal antibody; mCRC: metastatic colorectal cancer; EGFR: epidermal growth factor receptor; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; BRAF: v-Raf murine sarcoma viral oncogene homolog B.

**Table 2 Tumor genomic variants and potential targeted therapies of interest**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **Agents of Interest** | **Mechanism of Action** | **Phase** | **Trial Number1** | **Comment** |
| *FGFR* (*FGFR1, FGFR2, FGFR3, FGFR4*) | Ponatinib | Multi-kinase small molecule inhibitor | II | NCT02272998 |  |
|  | BGJ398 | Pan FGFR small molecule inhibitor | I | NCT01928459 |  |
| *RET* | Cabozantinib | Multi-kinase small molecule inhibitor | I | NCT02008383 | Cabozantinib + panitumumab |
|  | Vandetanib | Multi-kinase small molecule inhibitor | I | NCT01582191 |  |
|  | Apatinib | Multi-kinase small molecule inhibitor |  |  |  |
|  | Ponatinib | Multi-kinase small molecule inhibitor | II | NCT02272998 |  |
|  | RXDX-105 | RET and BRAF small molecule inhibtor | I | NCT01877811 |  |
|  | Sunitinib | Multi-kinase small molecule inhibitor |  |  |  |
|  | Sorafenib | Multi-kinase small molecule inhibitor | I | NCT01531361 |  |
|  |  |  |  |  |  |
| *HER-2* | AZD8931 | small molecule inhibitor of EGFR, HER-2, HER-3 | I/II | NCT01862003 | AZD8931 + FOLFIRI |
|  | Neratinib | small molecule inhibitor of EGFR, HER-2, HER-3 | II | NCT01953926 |  |
|  | HER-2 vaccine | B Cell Peptide Vaccine | I | NCT01376505 |  |
|  | T-DM1 | antibody-drug conjugate of traztuzumab and DM1 | II | HERACLES-RESCUE | At the time of traztumab failure |
|  | Pertuzumab | anti HER-2 monoclonal antibody | II | HERACLES | Pertuzumab + trastuzumab |
|  | Lapatinib | Anti HER-2 small molecule inhibitor | II | HERACLES | Lapatinib + trastuzumab |
| *c-MET* (*MET, HGFR*) | Crizotinib | Multi-kinase small molecule inhibitor |  | NCT02510001 | Crizotinib + PD-0325901 |
|  | Tivantinib | c-MET inhibitor |  | NCT01892527 | Tivantinib + Cetuximab |
|  | Cabozantinib | c-MET and VEGFR2 inhibitor |  |  |  |
|  | INC280 | small molecule inhibitor of c-MET | II | NCT2205398 | INC280+Cetuximab |
|  | AMG102 | HGF inhibitor |  |  |  |
|  | AV299 | HGF inhibitor |  |  |  |

1Utilizing the NCT number, clinical trial information can be obtained at <https://clinicaltrials.gov>. FGFR: Fibroblast growth factor receptor; EGFR: epidermal growth factor receptor; BRAF: v-Raf murine sarcoma viral oncogene homolog B; HER-2: Human growth factor receptor 2; HGFR: hepatocyte growth factor receptor; TDM-1: ado-trastuzumab emtansine; VEGFR: vascular endothelial growth factor receptor.

**Table 3 Current ongoing immune therapy trials for colorectal cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Agent** | **Class of Agent** | **Phase** | **Trial number1** | **Comment** |
| MK-3475 | anti-PD-1 mAb | II | NCT01876511 | MSI-high tumors |
| MEDI4736 | anti-PD-L1 mAb | I/II | NCT01693562 |  |
| Nivolumab +/- ipiliumumab | anti-PD-1 mAb/anti-CTLA-4 mAb | I/II | NCT02060188 | Recurrent and metastatic CRC |
| MK-3475 + mFOLFOX6 | anti-PD-1 mAb | II | NCT02375672 |  |
| Tremelimumab + MEDI4736 | anti-CTLA-4 mAb + anti-PD-L1 mAb | I | NCT01975831 |  |

1Utilizing the NCT number, clinical trial information can be obtained at <https://clinicaltrials.gov>. mAb: monoclonal antibody; CRC: colorectal cancer; MSI: microsatellite instability; CTLA: cytotoxic T associated lymphocyte protein; PD-1: program cell death protein 1; PD-L1: programmed cell death protein ligand 1; FOLFOX: combination of 5-Flurouracil, folinic acid and oxaliplatin chemotherapy regimen.